View article

Methods

This retrospective observational study was conducted on patients diagnosed with PTCL-EBV at Samsung Medical Center through a pathology review from 2000 to 2020. We analyzed the clinical data from 14 patients, immunohistochemistry and survival outcomes including overall survival and progression-free survival for each treatment regimen. Progression-free survival (PFS) was defined as the time from the start of chemotherapy to the confirmation of disease progression on imaging, and hematopoietic stem cell transplantation (HSCT) was considered as a consolidation treatment. Overall survival (OS) was defined as the time from diagnosis to the time of death.